Who
Laurie Stelzer
Director
Company insider
Files Form 4 as: Director, Sionna Therapeutics; Director, MBX Biosciences; Director, PMV Pharmaceuticals; Director, Spyre Therapeutics; Chief Financial Officer, Mirati Therapeutics; Director, Surface Oncology; EVP & Chief Financial Officer, Arena Pharmaceuticals; SVP, Chief Financial Officer, Halozyme Therapeutics.
In numbers
- Trades disclosed
- 99
- Buys
- 2
- Sells
- 1
- Bought
- $345K
- Sold
- $172K
- Companies
- 8
- Companies where not an officer
- 5
- First trade
- 15 Jun 2015
- Last trade
- 17 Jun 2026
- Last filed
- 18 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Jun 2026filed 18 Jun 2026 | SION Sionna Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,340 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | SION Sionna Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,340 at $0.00 | filing |
| 4 Jun 2026filed 5 Jun 2026 | MBX MBX Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 4 Jun 2026filed 5 Jun 2026 | MBX MBX Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 4 Jun 2026filed 5 Jun 2026 | PMVP PMV Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,000 at $0.00 | filing |
| 4 Jun 2026filed 5 Jun 2026 | PMVP PMV Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,000 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | SYRE Spyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,026 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | SYRE Spyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,026 at $0.00 | filing |
| 20 Jan 2026filed 22 Jan 2026 | MBX MBX Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,000 at $0.00 | filing |
| 20 Jan 2026filed 22 Jan 2026 | MBX MBX Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,000 at $0.00 | filing |
| 12 Jun 2025filed 16 Jun 2025 | SION Sionna Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,959 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | PMVP PMV Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,500 at $0.00 | filing |
| 29 May 2025filed 2 Jun 2025 | SYRE Spyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 6 Jun 2024filed 10 Jun 2024 | PMVP PMV Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —67,500 at $0.00 | filing |
| 14 May 2024filed 16 May 2024 | SYRE Spyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,323 at $0.00 | filing |
| 22 Nov 2023filed 27 Nov 2023 | SYRE Spyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 9 Aug 2023filed 10 Aug 2023 | Mirati Therapeutics | SEC FORM 4 Code A | $825K22,297 at $37.00 | filing |
| 8 Jun 2023filed 12 Jun 2023 | PMVP PMV Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,500 at $0.00 | filing |
| 2 Jun 2023filed 2 Jun 2023 | Mirati Therapeutics | SEC FORM 4 Sold | $172K4,647 at $37.06 | filing |
| 20 Jan 2023filed 24 Jan 2023 | Mirati Therapeuticsoption or derivative | SEC FORM 4 Code A | —45,456 at $0.00 | filing |
News
Halozyme Therapeutics (NASDAQ:HALO) CEO Sells $2,188,000.00 in StockHALO · themarketsdaily.com · 9 Oct 2026Halozyme Therapeutics (NASDAQ:HALO) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst SaysHALO · tickerreport.com · 8 Oct 2026
0 headlines in the last 90 days name Laurie Stelzer; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.